Novartis drug TasignaR meets primary endpoint in pivotal trial against GlivecR as first-line treatment in chronic myeloid leukemia patients

[Guest guest]

http://www.pipelinereview.com/index.php/2009102030206/Small-Molecules/Novart

is-drug-Tasigna-meets-primary-endpoint-in-pivotal-trial-against-Glivec-as-fi

rst-line-treatment-in-chronic-myeloid-leukemia-patients.html

Zavie (age 71)

67 Shoreham Avenue

Ottawa, Canada, K2G 3X3

dxd AUG/99

INF OCT/99 to FEB/00, CHF

No meds FEB/00 to JAN/01

Gleevec since MAR/27/01 (400 mg)

CCR SEP/01. #102 in Zero Club

2.8 log reduction Sep/05

3.0 log reduction Jan/06

2.9 log reduction Feb/07

3.6 log reduction Apr/08

3.6 log reduction Sep/08

3.7 log reduction Jan/09

3.8 log reduction May/09

3.8 log reduction Aug/09

e-mail: zmiller@...

Tel: 613-726-1117

Fax: 613-482-4801

Cell: 613-282-0204

ID: zaviem